ID
38390
Descripción
Study ID: 103414 Clinical Study ID: 103414 Study Title: A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal surgery Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00038961 https://clinicaltrials.gov/ct2/show/NCT00038961 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Fondaparinux Sodium Trade Name: Fondaparinux Sodium Study Indication: Thrombosis This phase III placebo-controlled trial studies the efficacy and safety of Fondaparinux as an additional prevention measure of venous thromboembolic events (VTE) in patients above the age of 40 with intermediate or high VTE risk undergoing abdominal surgery. The study consists of a Screening Visit (Visit 0), the baseline visit on Day 1, the day of the surgery (Visit 1), the treatment period (denoted in its entirety as Visit 2) consisting of administration of Fondaparinux (2.5mg subcutaneously once daily) or placebo starting on Day 1 and continuing at least up to Day 5, possibly up to Day 9, in parallel to intermittent pneumatic compression and possibly elastic stockings, followed by a mandatory bilateral venography no longer than 24 hours after study drug cessation, and finally a Follow-up Visit (Visit 3) on Day 30 +/- 2. This form contains whether and when the study drug has been given, and is to be filled in from Day 1 (Visit 1) possibly up to Day 9 (Visit 2), as well as the Randomization/Treatment Assignment, which is applicable to Day 1 (Visit 1) only (prior to the first injection).
Link
https://clinicaltrials.gov/ct2/show/NCT00038961
Palabras clave
Versiones (1)
- 15/10/19 15/10/19 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
15 de octubre de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Fondaparinux in Addition to Intermittent Pneumatic Compression in Abdominal Surgery Patients at VTE Risk - NCT00038961
Study Drug Dosing and Treatment Assignment
- StudyEvent: ODM
Descripción
Study Drug Dosing
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C0304229
Descripción
If no, specify reason
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1533734
Descripción
if applicable
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1521902
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C0304229
- UMLS CUI [1,4]
- C1533734
- UMLS CUI [1,5]
- C1272696
Descripción
Study Drug Dosing - per Day
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C0304229
- UMLS CUI-3
- C2826182
Descripción
Fill in entire itemgroup for each Day. Note: Day 1 = day of anesthesia induction The first post-operative dose will be 6 hours following surgical closure provided that hemostasis is achieved.Timing of the first post-operative injection of study drug requires strict adherence in patients ≥ 75years, and/or with a body weight < 50 kg and/or a creatinine clearance (cockroft formula) < 50 mLper minute. In these patients the first injection of study drug should be more than 6 hours after surgical closure.The first injection must be performed at least 4 hours after removing of indwelling intrathecal or epidural catheter.The second study drug injection will be 16 to 28 hours after the first injection.The third injection and the following will be once daily at 8:00 a.m. ±2.
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2826182
Descripción
If no, give date/time of dose in next item; if yes, specify reason
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0678766
- UMLS CUI [1,3]
- C1272696
Descripción
Select either "Not done" in previous item or give date/time of dose. The first post-operative dose will be 6 hours following surgical closure provided that hemostasis is achieved.Timing of the first post-operative injection of study drug requires strict adherence in patients ≥ 75years, and/or with a body weight < 50 kg and/or a creatinine clearance (cockroft formula) < 50 mLper minute. In these patients the first injection of study drug should be more than 6 hours after surgical closure.The first injection must be performed at least 4 hours after removing of indwelling intrathecal or epidural catheter.The second study drug injection will be 16 to 28 hours after the first injection.The third injection and the following will be once daily at 8:00 a.m. ±2.
Tipo de datos
datetime
Alias
- UMLS CUI [1,1]
- C1264639
- UMLS CUI [1,2]
- C0678766
- UMLS CUI [1,3]
- C0304229
Descripción
Must be completed only once, but, in case of error in treatment allocation, it must be recorded for each Day.
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1522541
Descripción
Reason dosing not done or outside requested time
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0566251
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C0678766
- UMLS CUI [1,4]
- C1272696
- UMLS CUI [2,1]
- C0566251
- UMLS CUI [2,2]
- C0304229
- UMLS CUI [2,3]
- C0678766
- UMLS CUI [2,4]
- C3242146
Descripción
Treatment Assignment
Alias
- UMLS CUI-1
- C1522541
Descripción
Date of randomization
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0011008
Descripción
Time of randomization
Tipo de datos
time
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0040223
Descripción
Treatment Number
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1522541
Descripción
Drug Label
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0013191
Similar models
Study Drug Dosing and Treatment Assignment
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
C2986440 (UMLS CUI [1,2])
C1533734 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C1533734 (UMLS CUI [1,4])
C1272696 (UMLS CUI [1,5])
C0304229 (UMLS CUI-2)
C2826182 (UMLS CUI-3)
C0678766 (UMLS CUI [1,2])
C1272696 (UMLS CUI [1,3])
C0678766 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,2])
C0678766 (UMLS CUI [1,3])
C1272696 (UMLS CUI [1,4])
C0566251 (UMLS CUI [2,1])
C0304229 (UMLS CUI [2,2])
C0678766 (UMLS CUI [2,3])
C3242146 (UMLS CUI [2,4])
C0011008 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])